Live tape
Top 8, mentions 7d9,474TSLA1,996 mentions▲ +0.05GOOGL1,538 mentions▲ +0.05NVDA1,158 mentions▲ +0.07CRWV1,139 mentions▲ +0.03SPCX1,032 mentions▲ +0.07QQQ1,002 mentions▲ +0.04META809 mentions▲ +0.05NBIS800 mentions▲ +0.05

Equity · Healthcare

XENE

NASDAQ

Xenon Pharmaceuticals Inc.

$33.50 −2.46% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 16, 2026
Price · Chart
21 sessions
$42.5 $32.5 18 Sep 16 Oct

The line runs $40 on 18 September through $33.50 on 16 October, on a scale from $32.5 to $42.5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 21 sessions, 18 Sep – 16 Oct 2026
Market cap $3.2B
52-week range $33.50 – $70.97
Avg volume 286.2K

as of Oct 16, 2026

XENE insider trades

SEC Form 4

XENE has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 8 December 2025.

Date Insider Type Shares Value
08 Dec 2025 MORTIMER IAN PRESIDENT & CEO Sell 10,830 $495K
05 Dec 2025 MORTIMER IAN PRESIDENT & CEO Sell 14,375 $647K
28 Nov 2025 MORTIMER IAN PRESIDENT & CEO Sell 97 $4K
01 Oct 2025 MORTIMER IAN PRESIDENT, CEO & INTERIM CFO Sell 25,000 $1.00M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
15 Oct 2025 Kelly Thomas Patrick Chief Financial Officer Award 255,000
01 Oct 2025 MORTIMER IAN PRESIDENT, CEO & INTERIM CFO Option exercise 25,000 $192K

XENE reported financials

SEC EDGAR XBRL SEC EDGAR

XENE reported revenue of $7.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$345.9M.

Figure Reported Period
Revenue $7.5M 31 Dec 2025 fiscal year
Net income −$345.9M 31 Dec 2025 fiscal year
Diluted EPS −$4.36 31 Dec 2025 fiscal year
Total assets $1.3B 30 Jun 2026 at period end
Total equity $1.2B 30 Jun 2026 at period end

XENE earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.11 —
31 Mar 2026 Q1 2026 −$1.17 —
31 Dec 2025 FY 2025 −$4.36 —
30 Sep 2025 Q3 2025 −$1.15 —
30 Jun 2025 Q2 2025 −$1.07 —
31 Mar 2025 Q1 2025 −$0.83 —
31 Dec 2024 FY 2024 −$3.01 —
30 Sep 2024 Q3 2024 −$0.81 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

XENE institutional holders

SEC Form 13F SEC EDGAR

13 of the 45 institutional funds we track reported a XENE position for the quarter ended 30 Jun 2026 — a combined $381.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Added +171.1% shares 1,642,848 $99.2M
Citadel Advisors Trimmed −47.2% shares 1,401,242 $84.6M
Marshall Wace New position 689,342 $41.6M
Tudor Investment Corp Held (±25%) +10.0% shares 545,387 $32.9M
Millennium Management Added +86.7% shares 376,777 $22.7M
Baker Bros. Advisors Held (±25%) 370,208 $22.3M
Man Group New position 310,617 $18.7M
Duquesne Family Office Held (±25%) 238,600 $14.4M
D. E. Shaw & Co. Added +1,082.3% shares 223,922 $13.5M
Balyasny Asset Management Held (±25%) −17.3% shares 193,407 $11.7M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SEC EDGARValuation computed from SEC EDGAR filings